Search

Your search keyword '"Peter L, Gross"' showing total 96 results

Search Constraints

Start Over You searched for: Author "Peter L, Gross" Remove constraint Author: "Peter L, Gross" Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
96 results on '"Peter L, Gross"'

Search Results

1. Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review

2. ARTS: A Large, International Trial of Thromboprophylaxis in Intra-abdominal, Gynecologic, and Urologic Surgery

3. Narrowing in on the True Rate of Venous Thromboembolism in Hospitalized Patients With COVID-19 Disease

4. Extended thromboprophylaxis following colorectal surgery in patients with inflammatory bowel disease: a comprehensive systematic clinical review

5. Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi

6. 10 years of Tolvaptan in ADPKD: A single center evaluation

7. Initiation of anticoagulation in atrial fibrillation by primary care physicians: Results of a telephone survey

8. AntiThrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC):study design and methodology for an international, adaptive Bayesian randomized controlled trial

9. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

10. Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis

11. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering

12. A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History

13. Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation

14. Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers?

15. Thrombus stability explains the factor V Leiden paradox: a mouse model

16. Thrombin generation and bleeding in cardiac surgery: a clinical narrative review

17. Thromboembolism in Older Adults

18. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

19. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

20. Canadian Urological Association guideline: Perioperative thromboprophylaxis and management of anticoagulation

21. Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study

22. Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation

23. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty

24. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study

25. OC4. Abstract Title: Thrombus Stability Explains the Factor V Leiden Paradox: A Mouse Model

26. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale

27. Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis

28. Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations

29. Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins

30. HS3ST1 Genotype Regulates Antithrombin’s Inflammomodulatory Tone and Associates with Atherosclerosis

31. Evolving use of new oral anticoagulants for treatment of venous thromboembolism

32. Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models

33. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study

34. 9. Abstract Title: Measurement of anti-factor Xa direct oral anticoagulant levels in the plasma samples from the perioperative anticoagulant use for surgery evaluation (PAUSE) study

35. Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale

36. New oral anticoagulants: which one should my patient use?

37. Emerging anticoagulant strategies

38. Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

39. Aspirin or Rivaroxaban for VTE Prophylaxis After Hip or Knee Arthroplasty

40. Inferior Vena Cava Ligation Rapidly Induces Tissue Factor Expression and Venous Thrombosis in Rats

41. Executive Summary: A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals

42. Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation

43. Vasopressin Antagonists as Aquaretic Agents for the Treatment of Hyponatremia

44. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation

45. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse

46. Extended venous thromboembolism prophylaxis comparing rivaroxaban to aspirin following total hip and knee arthroplasty

47. Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit)

48. Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle

49. Plasma fibronectin supports hemostasis and regulates thrombosis

50. The vaptans ante portas: a status report

Catalog

Books, media, physical & digital resources